No abstract

No abstract

No abstract

Urethane (ethyl carbamate) was administered intravenously to 30 patients in repeated doses of 0.2 Gm/kg body weight 3 times weekly every other week unless prohibitive toxicity occurred. The total duration of therapy ranged between one and 207 days and the total dose administered ranged between 20 and 280 Gm. Objective improvement occurred in 5 of 30 patients (16%). Subjective improvement occurred in 7 of 30 patients (23%). It is concluded that the usefulness of intravenous urethane is limited since objective improvement never occurred in more than one disease parameter despite significant hematopoietic toxicity.

No abstract